MK-2206 had synergetic effects with other mTOR inhibitors like RAD001 in cholangiocarcinoma and hepatocellular carcinoma (Grabinski et al., 2012; Ewald et al., 2013). This evidence concerns the gene MTOR and cholangiocarcinoma.